Navigation Links
A Weight Neutral Oral Antidiabetic Drug Would Earn a 25 Percent Patient Share in the Type 2 Diabetes Drug Market
Date:7/1/2008

Advantages in Efficacy and Safety Will Make Liraglutide the New Clinical

Gold Standard Drug by 2011, According to a New Report from Decision

Resources

WALTHAM, Mass., July 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a weight neutral oral antidiabetic drug would earn a 25 percent patient share in the treatment of type 2 diabetes, according to surveyed primary care physicians. Given the prices set for each of the drug profiles and the size of the type 2 diabetic patient population in 2011, a 25 percent patient share would result in sales of $4.1 billion for an agent fitting the report's Minimal Acceptable drug profile and $8.1 billion for an agent fitting the report's Major Achievement profile.

The new report entitled Type 2 Diabetes: Blockbuster-Bound Januvia Addresses Physicians' Concern over Hypoglycemia also finds that Novo Nordisk's liraglutide will become the new Decision Resources' proprietary clinical gold standard for the treatment of type 2 diabetes by 2011 as surveyed primary care physicians indicate that liraglutide has competitive advantages in terms of efficacy and safety in comparison to the current gold standard, metformin. Although liraglutide has disadvantages in the area of delivery because of its subcutaneous injectable formulation, its positive efficacy and safety attributes offset its disadvantage in delivery.

"Interviewed primary care physicians also state that liraglutide offers a considerable advantage over other current and emerging type 2 diabetes therapies in terms of weight loss," said Donny Wong, Ph.D., principal analyst at Decision Resources. "As a result, we forecast liraglutide to become the clinical gold standard among the agents covered in our analysis."

About the Report

Type 2 Diabetes: Blockbuster-Bound Januvia Addresses Physicians' Concern over Hypoglycemia is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

Elizabeth Marshall

Decision Resources

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. High Birth Weight Doubles Risk of Rheumatoid Arthritis
2. Weight Watchers Receives Adverse U.K. VAT Ruling
3. Heavy birthweight increases risk of developing rheumatoid arthritis
4. Heavy birthweight babies twice as likely to develop rheumatoid arthritis
5. One Year Later, Millions are Losing Weight with alli(R)
6. Weight gain within the normal range increases risk of chronic kidney disease
7. Big, Well-Balanced Breakfast Aids Weight Loss
8. Minimally-invasive weight loss surgery improves health and morbidly obese teens
9. Weight Loss After Gastric Bypass Is Key to Easing Diabetes
10. A Simple Weight Loss Diet: Scientific, Safe and Basically Free
11. Weight loss after gastric bypass surgery may protect against infection and cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... The annual time frame to change Medicare health ... is ending December 7th. Currently-enrolled Medicare beneficiaries who are looking to switch from their ... D) need to make changes during this period order for their new policy to ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... More than ... and while 84 percent of parents report speaking with their child about sex related ... sexually transmitted diseases. , Mediaplanet is proud to announce the launch of its second ...
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre Springs beneath the 5,000 ... unmatched natural purity of just 6 ppm TDS (Total Dissolved Solids) in addition to ... been available in several ShopRite and FoodTown stores in NJ and received rave comments ...
(Date:12/2/2016)... Miami, FL (PRWEB) , ... December 02, 2016 ... ... over 5,100 hot meals to needy individuals and families from eight different sites ... Florida on Thanksgiving Day. Over 1,000 volunteers worked very hard on Thanksgiving morning ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... they now offer a comprehensive in-house dental plan for all patients. Understanding that ... a plan that gives patients a number of perks, including discounts on many ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... YORK , December 2, 2016 ... Braces & Support) is Expected to Gain a Significant Market ... to Orthopedic Ailments  ... , According to ... Study on Medical Implants Sterile Packaging: Clamshell Product Type Segment ...
(Date:12/2/2016)... On Thursday, the NASDAQ Composite and ... the Dow Jones Industrial Average managed to stay in green. ... which prompted Stock-callers this morning to look at the performances ... NUVA ), Smith & Nephew PLC (NYSE: SNN ... Cesca Therapeutics Inc. (NASDAQ: KOOL ). You can ...
(Date:12/2/2016)... -- The concept of rare diseases and the idea that ... has been taking shape in Europe ... initiatives related to orphan medicinal products have been emerging at ... states individually. Many member states in the EU have led ... medicinal products, the result of which took the shape of ...
Breaking Medicine Technology: